Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Rein Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 0.71 · gapped above the open, then crossed back over prior close. High/low 0.75 at 9:30 am ET, 0.70 at 2:45 pm ET.
59 institutional managers report a position in Rein Therapeutics, Inc. worth $42.5M between them, filed on form 13F for the quarter ending 2026-06-30. 11 of them hold 80% of it, the largest being Voss Capital LLC at 12.88%.
34 more managers in the register
11 managers hold 80% of the $42.5M institutional base. The other 48 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 77 days old and does not move with the price above it.
via Voss Capital LLC, BIOS Capital Management, LP, Texas Capital Bank Wealth Management Services Inc +4 more · 12.88% of RNTX, 12.80% of ACTU
via Cable Car Capital LLC, Ikarian Capital, LLC, Boothbay Fund Management, LLC · 12.72% of RNTX, 13.18% of ACOG
via ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Boothbay Fund Management, LLC · 11.02% of RNTX, 29.66% of INM
via ADAR1 Capital Management, LLC, Great Point Partners LLC, Ikarian Capital, LLC +1 more · 11.02% of RNTX, 11.43% of AMAN
via Cable Car Capital LLC, Velan Capital Investment Management LP, Bleichroeder LP · 12.72% of RNTX, 28.65% of NSRX
via ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Boothbay Fund Management, LLC · 11.02% of RNTX, 9.71% of TRAW
Managers holding a meaningful stake in RNTX also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.
RNTX (Rein Therapeutics, Inc.) has 4 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.